- Home
- TPST vs KALA Comparison
TPST vs KALA Comparison
Compare TPST & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- KALA
- Stock Information
- Founded
- TPST 2011
- KALA 2009
- Country
- TPST United States
- KALA United States
- Employees
- TPST N/A
- KALA N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- KALA Health Care
- Exchange
- TPST Nasdaq
- KALA Nasdaq
- Market Cap
- TPST 33.0M
- KALA 26.2M
- IPO Year
- TPST N/A
- KALA 2017
- Fundamental
- Price
- TPST $6.92
- KALA $5.87
- Analyst Decision
- TPST Hold
- KALA Strong Buy
- Analyst Count
- TPST 3
- KALA 3
- Target Price
- TPST $30.00
- KALA $14.00
- AVG Volume (30 Days)
- TPST 86.6K
- KALA 125.3K
- Earning Date
- TPST 08-07-2025
- KALA 08-05-2025
- Dividend Yield
- TPST N/A
- KALA N/A
- EPS Growth
- TPST N/A
- KALA N/A
- EPS
- TPST N/A
- KALA N/A
- Revenue
- TPST N/A
- KALA N/A
- Revenue This Year
- TPST N/A
- KALA N/A
- Revenue Next Year
- TPST N/A
- KALA N/A
- P/E Ratio
- TPST N/A
- KALA N/A
- Revenue Growth
- TPST N/A
- KALA N/A
- 52 Week Low
- TPST $5.35
- KALA $2.92
- 52 Week High
- TPST $30.03
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- TPST 46.64
- KALA 60.68
- Support Level
- TPST $7.06
- KALA $4.36
- Resistance Level
- TPST $7.64
- KALA $7.00
- Average True Range (ATR)
- TPST 0.26
- KALA 0.71
- MACD
- TPST 0.00
- KALA 0.16
- Stochastic Oscillator
- TPST 22.10
- KALA 63.97
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.